Drug Profile


Alternative Names: 3,4-DAP; 3,4-DAP phosphate; 3,4-Diaminopyridine; Amifampridine phosphate; Firdapse; Zenas

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Assistance Publique Hopitaux de Paris
  • Developer BioMarin Pharmaceutical; Catalyst Pharmaceutical Partners; Fondazione Istituto Neurologico Carlo Besta
  • Class Aminopyridines; Small molecules
  • Mechanism of Action Acetylcholine stimulants; Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Lambert-Eaton myasthenic syndrome; Congenital myasthenic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Lambert-Eaton myasthenic syndrome
  • Preregistration Congenital myasthenic syndromes
  • Phase II/III Myasthenia gravis

Most Recent Events

  • 09 Aug 2017 Catalyst Pharmaceuticals completes a proof of concept phase II/III trial in Myasthenia gravis (MuSK Ab seropositive) before August 2017
  • 16 Mar 2017 Efficacy data from phase II/III trial in Myasthenia gravis released by Catalyst Pharmaceuticals
  • 15 Dec 2016 Catalyst Pharmaceuticals enrols first patient in the phase III LEMS-003 trial for Lambert-Eaton myasthenic syndrome in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top